Janssen submits European extension marketing authorisation application for paliperidone palmitate
First long-acting treatment to be administered four times a year for the treatment of schizophrenia in adults
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Psychiatry Patient care antipsychotic Latest News long-acting therapy paliperidone palmitate schizophrenia xeplion Source Type: news
More News: Clinical Trials | Drugs & Pharmacology | Invega | Invega Sustenna | Marketing | Psychiatry | Schizophrenia